Biotherapeutics Inc said itscooperative findings on interleukin-2, the anti-cancer drug,were published today in the "New England Journal of Medicine".    Biotherapeutics, along with the Biological TherapyInstitute and the National Cancer Institute, said thepublication focused on a reduction in toxicity through the useof a constant infusion mode of intravenous administrationprotocol. Reuter&#3;